Drug Trials

(For ADPKD)

Tolvaptan | Otsuka Maryland Research Institute
This study, which recently received “fast track” designation by the Food and Drug Administration because of its promise as a treatment for PKD, is looking at the effectiveness of a vasopressin antagonist drug to slow or stop cyst growth in ADPKD patients. Phase II clinical trials are finishing up. Enrollment has not yet begun for Phase III clinical trials. Phase III trials are larger studies looking at drug effectiveness in ADPKD patients living in the Americas, Asia, and Europe. Contact Otsuka at 866-712-5837 for more information.

Rapamycin (Slrolimus/Rapamune)
This study is a Phase I/Phase II prospective, randomized, placebo-controlled clinical trial sponsored bye the Cleveland Clinic and designed to evaluate the effects of an agent (Rapamycin) that has antiproliferative, antiangiogenesis and tumor-progression blocking capabilities. This study is not yet open for patient recruitment. For more information, type in “polycystic kidney disease” and select “Pilot Study of Rapamycin as Treatment for Autosomal Dominant PKD.”

Somatostatin
This general aim of this study is to compare the effects on disease progression of three year treatment regimen using long-acting Somatostatin or placebo in patients with ADPKD and normal renal function or mild to moderate renal insufficiency. This is a Phase III study sponsored by the Mario Negri Institute for Pharmacological Research in Bergamo, Italy. This study is not yet open for patient recruitment. For more information, go to www.clinicaltrials.gov/ct/ and type in “polycystic kidney disease”. Then select “Somatostatin in Polycystic Kidney: A Long-Term Three Year Follow-up Study.”